{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-021095","form_type":"8-K","ticker":"MNKD","cik":"0000899460","company_name":"MANNKIND CORP","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.226527+00:00","generated_at":"2026-06-05T13:55:31.145370+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"MannKind FY 2023 revenue doubled to $199M; Q4 posts GAAP net income of $1M","bullets":["FY 2023 total revenues $199M, +99% YoY; Q4 revenues $58M, +62% YoY.","Q4 2023 net income of $1M (GAAP); Non-GAAP net income of $7M.","Afrezza Q4 net revenue $15.5M (+29%); Tyvaso DPI royalties Q4 $21.0M (+132%).","Cash $302.3M at year-end; plans Phase 3 for MNKD-101 and Phase 1 for MNKD-201 in H1 2024.","Commercial product gross margin 70% in Q4 vs 77% prior year; lower due to cost timing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-021095","json":"https://secwatch.observer/filing/0000950170-24-021095.json","markdown":"https://secwatch.observer/filing/0000950170-24-021095.md","text":"https://secwatch.observer/filing/0000950170-24-021095.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899460/000095017024021095/0000950170-24-021095-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899460/000095017024021095/mnkd-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T13:55:31.145370+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"91ed10cc2b8857f1861327ca8e1d7445bc9e919b","claim":"MANNKIND CORP reported the quarter and full year ended December 31, 2023 results: revenue Total revenues of $199M, net income 4Q 2023 Net income of $1M.","evidence_excerpt":"REPORTS 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS: PROVIDES CLINICAL DEVELOPMENT UPDATE Conference Call to Begin Today at 5:00 p.m. (ET) • 2023 Total revenues of $199M; +99% vs. 2022 • 4Q 2023 Total revenues of $58M; +62% vs. 2022 • 4Q 2023 Net income of $1M; Non-GAAP net income of $7M • $302M of cash and cash equivalents and investments at","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/899460/000095017024021095/0000950170-24-021095-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"Total revenues of $199M"},{"label":"Net income","value":"4Q 2023 Net income of $1M"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}